Patent 7338772 was granted and assigned to Schering on March, 2008 by the United States Patent and Trademark Office.
The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.